🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with figures suggesting over 82 million infections each year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The study enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals directly involved have expressed optimism. Having a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the infection for people and to prevent the spread of extremely resistant gonorrhoea globally.